Register for our free email digests:
Latest From Rebiotix Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
US FDA's popular breakthrough therapy designation given to Proteon's vonapanitase for dialysis patients, Synthetic Biologics' ribaxamase to prevent C. difficile infection, and River Vision's teprotumumab for thyroid eye disease; Vericel's cell therapy for heart failure is designated a regenerative medicine advanced therapy.
Switzerland’s Ferring is diving deep into the microbiome, looking at a range of potential therapy platforms including bacteriophage and probiotics. Its CSO believes a microbiome-based therapeutic approach could benefit dermatological and women’s health conditions, as well as gastro-intestinal disorders.
- Therapeutic Areas
- Infectious & Viral Diseases
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Rebiotix Inc.
- Senior Management
Lee Jones, Pres. & CEO
Ken Blount, PhD, Head, External Research
Greg Fluet, CBO
- Contact Info
2660 Patton Rd.
Roseville, MN 55113
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.